CHICAGO (MedPage Today) -- An FDA meta-analysis supported response rate as a surrogate endpoint in metastatic non-small cell lung cancer, but others said it?s time to look beyond conventional measures. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment